The tiny magnetic particles of the Magtrace® lymphatic tracer are optimized to take the same path a spreading cancer cell would through the lymphatic system, making it an ideal tracer for sentinel lymph node biopsy procedures.
The Magtrace® lymphatic tracer is a liquid tracer that has been developed specifically for sentinel node biopsies. Detected by our Sentimag® localization system, this non-radioactive tracer directs surgeons to the first draining lymph nodes most likely to contain cancer to help determine if it has spread.
This simple liquid allows any patient or any hospital to access the highest standard in breast cancer staging.
Just one injection required, compared to radioisotope and blue dye.
Can be injected weeks ahead of the surgery or as little as 20 minutes before the procedure begins††
The tiny particles are optimized for nodes, providing a clear signal and visual when performing sentinel node biopsy procedures.
No unpleasant sensations or risk of anaphylaxis like blue dye.†
No radiation exposure or limitations on supply and storage.
Eliminate unnecessary axilla surgery with Delayed SLNB, only possible with Magtrace.
...a real game-changer in the way we treat breast cancer in the United States.
Join the hundreds of physicians using the Sentimag® platform and Magtrace® lymphatic tracer to give their patients the best possible care.
*Data on file at Endomag. †Clinical references available on our Clinical data page. ††*For simple mastectomy patients.
Indications may vary in different countries; please either visit our Indications page, consult the appropriate IFU or your local distributor for more information.